Research Library
Compound Research Profiles·Comparative Science·4 min read

GLP-1, Dual Agonists, and Triple Agonists: A Receptor-Level Comparison

More receptor targets can mean broader effects, broader hypotheses, and broader uncertainty.

By
Jacob Doyon, Researcher, Cendrix
Reviewed by
Jacob Leisher, Researcher, Cendrix
Published
June 9, 2026
Last reviewed
June 26, 2026

Single-target does not mean simple

Semaglutide activates the GLP-1 receptor, influencing glucose-dependent insulin secretion, glucagon, gastric emptying, and central satiety pathways. Its extensive development program provides a mature evidence base for approved products.

Dual agonism adds GIP signaling

Tirzepatide activates GIP and GLP-1 receptors. The two pathways overlap but are not identical, and the combined molecule has its own sequence, receptor balance, pharmacokinetics, and clinical evidence.

Triple agonism adds glucagon-receptor activity

Retatrutide adds glucagon-receptor agonism to GIP and GLP-1 activity. That creates hypotheses involving energy expenditure, liver metabolism, and body composition, while also adding cardiovascular and metabolic questions. It remains investigational.

Receptor balance is a design variable

A multi-agonist is not simply three drugs added together. Relative potency, tissue expression, exposure, receptor desensitization, and downstream bias shape the observed effect.

Evidence maturity differs

Approved semaglutide and tirzepatide products have extensive controlled evidence and regulated manufacturing. Retatrutide has meaningful human trials but no FDA approval as of June 2026.

This article is provided for scientific and educational purposes. It does not describe or recommend human or veterinary use. Research findings may be limited by study design, model selection, material identity, sample size, or lack of independent replication.

Cendrix analysis

Cendrix compares these molecules at the receptor and evidence level, not as consumer options. More targets can create broader effects, but also broader uncertainty.

Selected primary references

  1. [1]FDA concerns with unapproved GLP-1 products
  2. [2]Retatrutide phase 2 trial
  3. [3]FDA peptide guidance

Editorial note. Written by Jacob Doyon and scientifically reviewed by Jacob Leisher. See our editorial standards, citation policy, and corrections policy.